PL2692346T3 - Przeciwwirusowa pochodna 1 -fenylo-2,5-dibenzimidazol-5-ilo-pirolidyny - Google Patents

Przeciwwirusowa pochodna 1 -fenylo-2,5-dibenzimidazol-5-ilo-pirolidyny

Info

Publication number
PL2692346T3
PL2692346T3 PL13191041T PL13191041T PL2692346T3 PL 2692346 T3 PL2692346 T3 PL 2692346T3 PL 13191041 T PL13191041 T PL 13191041T PL 13191041 T PL13191041 T PL 13191041T PL 2692346 T3 PL2692346 T3 PL 2692346T3
Authority
PL
Poland
Prior art keywords
dibenzimidazol
antiviral
phenyl
pyrrolidine derivative
pyrrolidine
Prior art date
Application number
PL13191041T
Other languages
English (en)
Inventor
David A Degoey
Warren M Kati
Charles W Hutchins
Pamela L Donner
Allan C Krueger
John T Randolph
Christopher E Motter
Lissa T Nelson
Sachel V Patel
Mark A Matulenko
Ryan G Keddy
Tammie K Jinkerson
Yi Gao
Dachun Liu
John K Pratt
Todd W Rockway
Clarence J Maring
Douglas K Hutchinson
Charles A Flentge
Rolf Wagner
Michael D Tufano
David A Betebenner
Kathy Sarris
Kevin R Woller
Sebel H Wagaw
Jean C Califano
Wenke Li
Daniel D Caspi
Mary E Bellizzi
William A Carroll
Original Assignee
Abbvie Bahamas Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44860553&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL2692346(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from US12/903,822 external-priority patent/US20110092415A1/en
Application filed by Abbvie Bahamas Ltd filed Critical Abbvie Bahamas Ltd
Publication of PL2692346T3 publication Critical patent/PL2692346T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4355—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/695—Silicon compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C07D491/113—Spiro-condensed systems with two or more oxygen atoms as ring hetero atoms in the oxygen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/02—Silicon compounds
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/582—Recycling of unreacted starting or intermediate materials

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
PL13191041T 2010-10-13 2011-10-12 Przeciwwirusowa pochodna 1 -fenylo-2,5-dibenzimidazol-5-ilo-pirolidyny PL2692346T3 (pl)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US12/903,822 US20110092415A1 (en) 2009-06-11 2010-10-13 Anti-Viral Compounds
US12/964,027 US8921514B2 (en) 2009-06-11 2010-12-09 Anti-viral compounds
US201161446800P 2011-02-25 2011-02-25
US13/100,827 US8937150B2 (en) 2009-06-11 2011-05-04 Anti-viral compounds
EP13191041.6A EP2692346B1 (en) 2010-10-13 2011-10-12 An antiviral 1-phenyl-2,5-dibenzimidazol-5-yl-pyrrolidine derivative
EP11773371.7A EP2627651A1 (en) 2010-10-13 2011-10-12 Anti-viral compounds

Publications (1)

Publication Number Publication Date
PL2692346T3 true PL2692346T3 (pl) 2016-05-31

Family

ID=44860553

Family Applications (1)

Application Number Title Priority Date Filing Date
PL13191041T PL2692346T3 (pl) 2010-10-13 2011-10-12 Przeciwwirusowa pochodna 1 -fenylo-2,5-dibenzimidazol-5-ilo-pirolidyny

Country Status (28)

Country Link
US (5) US8937150B2 (pl)
EP (4) EP2692346B1 (pl)
JP (1) JP5834085B2 (pl)
KR (2) KR101586215B1 (pl)
CN (3) CN103153988B (pl)
AR (1) AR083398A1 (pl)
AU (1) AU2011316506B2 (pl)
BR (1) BR112013005701B1 (pl)
CA (1) CA2807847C (pl)
CO (1) CO6761348A2 (pl)
CY (1) CY2017031I1 (pl)
DO (1) DOP2013000078A (pl)
EA (2) EA024100B1 (pl)
EC (1) ECSP13012622A (pl)
FR (1) FR17C1040I2 (pl)
GT (1) GT201300093A (pl)
LT (1) LTC2692346I2 (pl)
LU (1) LUC00038I2 (pl)
MX (2) MX344092B (pl)
NL (1) NL300901I2 (pl)
NO (2) NO2017057I2 (pl)
NZ (1) NZ606645A (pl)
PE (2) PE20140038A1 (pl)
PL (1) PL2692346T3 (pl)
SG (1) SG188951A1 (pl)
TW (1) TWI419874B (pl)
UY (2) UY33667A (pl)
WO (1) WO2012051361A1 (pl)

Families Citing this family (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102245604A (zh) 2008-12-23 2011-11-16 雅培制药有限公司 抗病毒化合物
CN102264737A (zh) 2008-12-23 2011-11-30 雅培制药有限公司 抗病毒化合物
EP2419404B1 (en) * 2009-04-15 2015-11-04 AbbVie Inc. Anti-viral compounds
US8937150B2 (en) 2009-06-11 2015-01-20 Abbvie Inc. Anti-viral compounds
US8716454B2 (en) 2009-06-11 2014-05-06 Abbvie Inc. Solid compositions
US9394279B2 (en) * 2009-06-11 2016-07-19 Abbvie Inc. Anti-viral compounds
NZ591973A (en) * 2009-06-11 2013-03-28 Abbott Lab Anti-viral compounds to treat hcv infection
CN104530079B (zh) * 2009-12-18 2017-10-20 北京凯因科技股份有限公司 C型肝炎病毒复制的新型抑制剂
CA2784748A1 (en) 2009-12-18 2011-06-23 Idenix Pharmaceuticals, Inc. 5,5-fused arylene or heteroarylene hepatitis c virus inhibitors
NZ605440A (en) 2010-06-10 2014-05-30 Abbvie Bahamas Ltd Solid compositions comprising an hcv inhibitor
HUE026832T2 (en) * 2010-10-13 2016-07-28 Abbvie Bahamas Ltd Antiviral 1-phenyl-2,5-dibenzimidazol-5-ylpyrrolidine derivative
US8552047B2 (en) 2011-02-07 2013-10-08 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US9546160B2 (en) 2011-05-12 2017-01-17 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US10201584B1 (en) 2011-05-17 2019-02-12 Abbvie Inc. Compositions and methods for treating HCV
WO2013030750A1 (en) 2011-09-01 2013-03-07 Lupin Limited Antiviral compounds
US9034832B2 (en) 2011-12-29 2015-05-19 Abbvie Inc. Solid compositions
EP2907505A3 (en) * 2011-12-29 2015-12-30 Abbvie Inc. Solid compositions comprising an HCV inhibitor
US9326973B2 (en) 2012-01-13 2016-05-03 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US9073943B2 (en) 2012-02-10 2015-07-07 Lupin Limited Antiviral compounds with a dibenzooxaheterocycle moiety
EP3597190A1 (en) * 2012-09-18 2020-01-22 AbbVie Inc. Methods for treating hepatitis c
AU2013318309A1 (en) * 2012-09-18 2015-04-02 Abbvie Inc. Methods for treating hepatitis C
US20140212491A1 (en) 2013-01-31 2014-07-31 Gilead Pharmasset Llc Combination formulation of two antiviral compounds
US20180042982A1 (en) * 2013-03-14 2018-02-15 Abbvie Inc. Methods for Treating HCV
US11484534B2 (en) * 2013-03-14 2022-11-01 Abbvie Inc. Methods for treating HCV
CN108187056A (zh) * 2013-03-14 2018-06-22 艾伯维公司 用于治疗hcv患者的直接作用的抗病毒剂和利巴韦林的组合
ES2624980T3 (es) * 2013-03-14 2017-07-18 Abbvie Inc. Combinación de dos antivirales para el tratamiento de la hepatitis C
US20200368229A9 (en) * 2013-03-14 2020-11-26 Abbvie Inc. Methods for Treating HCV
US20150023913A1 (en) 2013-07-02 2015-01-22 Bristol-Myers Squibb Company Hepatitis C Virus Inhibitors
US9717712B2 (en) 2013-07-02 2017-08-01 Bristol-Myers Squibb Company Combinations comprising tricyclohexadecahexaene derivatives for use in the treatment of hepatitis C virus
JP2016527232A (ja) 2013-07-17 2016-09-08 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ Ｈｃｖの治療に使用するためのビフェニル誘導体を含む組み合わせ
EP4005560A1 (en) 2013-08-27 2022-06-01 Gilead Pharmasset LLC Combination formulation of two antiviral compounds
PL3043803T3 (pl) 2013-09-11 2022-11-07 Emory University Kompozycje nukleotydowe i nukleozydowe oraz ich zastosowanie
WO2015103490A1 (en) 2014-01-03 2015-07-09 Abbvie, Inc. Solid antiviral dosage forms
AU2015240753B2 (en) * 2014-04-02 2020-01-16 Abbvie Inc. Methods for treating HCV
MX2016012799A (es) 2014-04-02 2016-12-12 Abbvie Inc Metodos para tratar el virus de la hepatitis c.
CN106458989A (zh) * 2014-05-09 2017-02-22 艾伯维公司 晶型
WO2016053869A1 (en) * 2014-09-29 2016-04-07 Abbvie Inc. Solid forms of anti-viral compounds
WO2016134054A1 (en) 2015-02-18 2016-08-25 Abbvie Inc. Anti-viral compounds
WO2016134051A1 (en) 2015-02-18 2016-08-25 Abbvie Inc. Anti-viral compounds
WO2016134050A1 (en) 2015-02-18 2016-08-25 Abbvie Inc. Anti-viral compounds
WO2016134056A1 (en) 2015-02-18 2016-08-25 Abbvie Inc. Anti-viral compounds
WO2016134057A1 (en) 2015-02-18 2016-08-25 Abbvie Inc. Anti-viral compounds
WO2016134058A1 (en) 2015-02-18 2016-08-25 Abbvie Inc. Combinations useful to treat hepatitis c virus
WO2016134053A1 (en) 2015-02-18 2016-08-25 Abbvie Inc. Anti-viral compounds
GB201506660D0 (en) 2015-04-20 2015-06-03 Cellcentric Ltd Pharmaceutical compounds
GB201506658D0 (en) 2015-04-20 2015-06-03 Cellcentric Ltd Pharmaceutical compounds
JO3637B1 (ar) 2015-04-28 2020-08-27 Janssen Sciences Ireland Uc مركبات بيرازولو- وترايازولو- بيريميدين مضادة للفيروسات rsv
US20160375017A1 (en) 2015-06-26 2016-12-29 Abbvie Inc. Solid Pharmaceutical Compositions for Treating HCV
US10617675B2 (en) 2015-08-06 2020-04-14 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
EP3344642A1 (en) 2015-09-02 2018-07-11 AbbVie Inc. Anti-viral tetrahydrofurane derivatives
WO2017061575A1 (ja) * 2015-10-07 2017-04-13 日産化学工業株式会社 液晶配向剤、液晶配向膜、及び液晶表示素子
HRP20211960T1 (hr) 2016-03-22 2022-03-18 Merck Sharp & Dohme Corp. Alosterični modulatori nikotinskih acetilcolinskih receptora
WO2017189978A1 (en) 2016-04-28 2017-11-02 Emory University Alkyne containing nucleotide and nucleoside therapeutic compositions and uses related thereto
CN110382487B (zh) * 2017-03-22 2021-04-02 正大天晴药业集团股份有限公司 用于抗丙型肝炎病毒感染的含硅化合物
GB201706806D0 (en) 2017-04-28 2017-06-14 Sentinel Oncology Ltd Pharmaceutical compounds
CA2981993A1 (en) * 2017-08-02 2019-02-02 Abbvie Inc. Methods for treating hcv
US20200330460A1 (en) * 2017-09-01 2020-10-22 Abbvie Inc. Methods for Treating HCV
TW201932470A (zh) 2017-11-29 2019-08-16 愛爾蘭商健生科學愛爾蘭無限公司 具有抗ｒｓｖ活性之吡唑并嘧啶
EP3746444B1 (en) 2018-01-31 2023-09-27 Janssen Sciences Ireland Unlimited Company Cycloalkyl substituted pyrazolopyrimidines having activity against rsv
CA3093802A1 (en) 2018-03-13 2019-09-19 Shire Human Genetic Therapies, Inc. Substituted imidazopyridines as inhibitors of plasma kallikrein and uses thereof
ES2957316T3 (es) 2018-04-23 2024-01-17 Janssen Sciences Ireland Unlimited Co Compuestos heteroaromáticos que tienen actividad contra VSR
EP3843712A4 (en) * 2018-08-29 2022-08-17 Abbvie Inc. METHOD FOR MANUFACTURING ACTIVE DRUG SUBSTANCE OF PIBRENTASVIR
WO2020207263A1 (zh) * 2019-04-08 2020-10-15 四川科伦博泰生物医药股份有限公司 苯并咪唑化合物、其制备方法及其用途
CN114728962A (zh) 2019-09-18 2022-07-08 武田药品工业有限公司 血浆激肽释放酶抑制剂及其用途
US11370803B2 (en) 2019-09-18 2022-06-28 Takeda Pharmaceutical Company Limited Heteroaryl plasma kallikrein inhibitors
CN115594591A (zh) * 2021-06-28 2023-01-13 凯特立斯（深圳）科技有限公司（Cn） 一种催化不对称氢化制备哌仑他韦中间体的方法

Family Cites Families (200)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE75755C (de) 1894-06-14 DAHL & COMP, in Barmen Verfahren zur Darstellung von aromatisch substituirten Amidodinaphtylmethanen.
DE3132020A1 (de) * 1981-08-13 1983-03-03 Basf Ag, 6700 Ludwigshafen N-benzoyl-n'-phenylharnstoffe, verfahren zu ihrer herstellung und ihre verwendung zur bekaempfung von insekten und spinnentieren
IT1227260B (it) 1988-09-30 1991-03-28 Himont Inc Dieteri utilizzabili nella preparazione di catalizzatori ziegler-natta
JPH09504266A (ja) 1993-05-24 1997-04-28 スミスクライン・ビーチャム・コーポレイション 血液調節ペプチド
US5683999A (en) 1995-03-17 1997-11-04 The Dupont Merck Pharmaceutical Company Cyclic urea HIV protease inhibitors
SI9500173B (sl) 1995-05-19 2002-02-28 Lek, Trofazna farmacevtska oblika s konstantnim in kontroliranim sproščanjem amorfne učinkovine za enkrat dnevno aplikacijo
US6037157A (en) 1995-06-29 2000-03-14 Abbott Laboratories Method for improving pharmacokinetics
US5935982A (en) 1997-02-28 1999-08-10 The University Of North Carolina At Chapel Hill Methods of treating retroviral infection and compounds useful therefor
US6235493B1 (en) 1997-08-06 2001-05-22 The Regents Of The University Of California Amino acid substituted-cresyl violet, synthetic fluorogenic substrates for the analysis of agents in individual in vivo cells or tissue
US6919366B2 (en) 1998-05-22 2005-07-19 Avanir Pharmaceuticals Benzimidazole derivatives as modulators of IgE
US6369091B1 (en) 1998-05-22 2002-04-09 Avanir Pharmaceuticals Benzimidazole analogs as down-regulators of IgE
CA2332989A1 (en) 1998-05-22 1999-12-02 Avanir Pharmaceuticals Benzimidazole derivatives as modulators of ige
US6911462B2 (en) 1998-05-22 2005-06-28 Avanir Pharmaceuticals Benzimidazole compounds for regulating IgE
KR100336090B1 (ko) 1998-06-27 2002-05-27 윤승원 오일, 지방산 또는 이들의 혼합물을 함유한 난용성 약물의 고형분산제제
US6387885B1 (en) 1998-08-26 2002-05-14 Abbott Laboratories 3′,3′-N-bis-desmethyl-3′-N-cycloalkyl erythromycin derivatives as LHRH antagonists
US6248363B1 (en) 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
DE19913692A1 (de) 1999-03-25 2000-09-28 Basf Ag Mechanisch stabile pharmazeutische Darreichungsformen, enthaltend flüssige oder halbfeste oberflächenaktive Substanzen
ES2245955T3 (es) 1999-12-21 2006-02-01 Sugen, Inc. 7-aza-indolin-2-onas 4-sustituidas y su utilizacion como inhibidores de proteina-quinasa.
IL151934A0 (en) 2000-04-05 2003-04-10 Schering Corp Macrocyclic ns3-serine protease inhibitors of hepatitis c virus comprising n-cyclic p2 moieties
DE10026698A1 (de) 2000-05-30 2001-12-06 Basf Ag Selbstemulgierende Wirkstoffformulierung und Verwendung dieser Formulierung
US7065453B1 (en) 2000-06-15 2006-06-20 Accelrys Software, Inc. Molecular docking technique for screening of combinatorial libraries
WO2002014314A2 (en) 2000-08-14 2002-02-21 Ortho Mcneil Pharmaceutical, Inc. Substituted pyrazoles
US6388093B1 (en) 2001-01-05 2002-05-14 Sun Chemical Corporation Syntheses for preparing 1,4-diketopyrrolo [3,4-c]pyrroles
EP2206709A3 (en) 2001-06-11 2011-06-29 Virochem Pharma Inc. Thiophene derivatives as antiviral agents for flavivirus infection
EP2335700A1 (en) 2001-07-25 2011-06-22 Boehringer Ingelheim (Canada) Ltd. Hepatitis C virus polymerase inhibitors with a heterobicylic structure
RU2286343C2 (ru) 2001-08-10 2006-10-27 Орто-Макнейл Фармасьютикал, Инк. Замещенные пиразолы
AU2003216274A1 (en) 2002-02-11 2003-09-04 Neurocrine Biosciences, Inc. Pyrrole derivatives as ligands of melanocortin receptors
TW200304820A (en) 2002-03-25 2003-10-16 Avanir Pharmaceuticals Use of benzimidazole analogs in the treatment of cell proliferation
JP3925265B2 (ja) 2002-03-25 2007-06-06 コニカミノルタホールディングス株式会社 有機エレクトロルミネッセンス素子及びそれを用いた表示装置
PL374190A1 (pl) 2002-06-14 2005-10-03 Merck & Co, Inc. Inhibitory kinezyny mitotycznej
CA2491895C (en) 2002-07-09 2011-01-18 Vertex Pharmaceuticals Incorporated Inhibitors of c-jun n-terminal kinases (jnk) and other protein kinases
AU2003264038A1 (en) 2002-08-12 2004-02-25 Bristol-Myers Squibb Company Combination pharmaceutical agents as inhibitors of hcv replication
KR100482276B1 (ko) * 2002-08-12 2005-04-13 한국과학기술연구원 피롤계 화합물, 그 중합체 및 이들을 이용한 ｅｌ 소자
GB0229518D0 (en) 2002-12-19 2003-01-22 Astrazeneca Ab Chemical compounds
TW200508224A (en) 2003-02-12 2005-03-01 Bristol Myers Squibb Co Cyclic derivatives as modulators of chemokine receptor activity
EP2246333B1 (en) * 2003-05-22 2012-10-24 Abbott Laboratories Indazole, benzisoxazole, and benzisothiazole kinase inhibitors
US8025899B2 (en) 2003-08-28 2011-09-27 Abbott Laboratories Solid pharmaceutical dosage form
TW200518669A (en) 2003-09-12 2005-06-16 Vertex Pharma Animal model for protease activity and liver damage
US20060003942A1 (en) 2003-10-27 2006-01-05 Roger Tung Combinations for HCV treatment
US7582770B2 (en) * 2004-02-20 2009-09-01 Boehringer Ingelheim International Gmbh Viral polymerase inhibitors
BRPI0401908A (pt) 2004-06-04 2006-01-17 Univ Rio De Janeiro Compostos inibidores de serina protease, processo de obtenção e uso para tratamento de flaviviroses
US7772271B2 (en) 2004-07-14 2010-08-10 Ptc Therapeutics, Inc. Methods for treating hepatitis C
US20090208456A1 (en) 2004-07-27 2009-08-20 Gilead Sciences, Inc. Imidazo[4,5-d]pyrimidines, their uses and methods of preparation
BRPI0514316A (pt) 2004-08-13 2008-06-10 Praecis Pharm Inc métodos e composições para modulação de atividade de receptor de esfingosina-1-fosfato (s1p)
CN101027291A (zh) * 2004-09-24 2007-08-29 阿斯利康(瑞典)有限公司 苯并咪唑衍生物以及它们作为大麻素受体配体的用途
TW200633718A (en) * 2004-12-16 2006-10-01 Applied Research Systems Treatment of hepatitis c in the asian population
MX2007009313A (es) 2005-02-01 2007-09-12 Wyeth Corp Amino-piridinas como inhibidores de ????-secretasa.
WO2006088711A1 (en) 2005-02-14 2006-08-24 Wyeth AZOLYLACYLGUANIDINES AS β-SECRETASE INHIBITORS
US7894996B2 (en) 2005-02-28 2011-02-22 The Rockefeller University Structure of the hepatitis C NS5A protein
US8143288B2 (en) 2005-06-06 2012-03-27 Bristol-Myers Squibb Company Inhibitors of HCV replication
PE20070099A1 (es) 2005-06-30 2007-02-06 Janssen Pharmaceutica Nv N-heteroarilpiperazinil ureas como moduladores de la amida hidrolasa del acido graso
WO2007011284A1 (en) 2005-07-15 2007-01-25 Astrazeneca Ab Therapeutic agents
WO2007070556A2 (en) 2005-12-12 2007-06-21 Genelabs Technologies, Inc. N-(6-membered aromatic ring)-amido anti-viral compounds
BRPI0619730A2 (pt) 2005-12-12 2011-10-11 Genelabs Tech Inc compostos antivirais de n-(anel aromático de 5 membros)-amido
ES2378473T3 (es) 2005-12-21 2012-04-12 Abbott Laboratories Compuestos antivirales
EP1971611B1 (en) 2005-12-21 2012-10-10 Abbott Laboratories Anti-viral compounds
CA2634699A1 (en) 2005-12-21 2007-06-28 Decode Genetics Ehf N-linked aryl heteroaryl inhibitors of lta4h for treating inflammation
US7763731B2 (en) 2005-12-21 2010-07-27 Abbott Laboratories Anti-viral compounds
WO2007082554A1 (en) 2006-01-23 2007-07-26 Istituto Di Ricerche Di Biologia Molecolare P Angeletti Spa Modulators of hcv replication
AU2007250443B2 (en) 2006-05-16 2013-06-13 Pharmascience Inc. IAP BIR domain binding compounds
JP2007320925A (ja) 2006-06-02 2007-12-13 Mitsubishi Chemicals Corp トリアリールアミン系化合物並びにそれを用いた電子写真感光体及び画像形成装置
EP2029609A2 (en) 2006-06-08 2009-03-04 Eli Lilly & Company Novel mch receptor antagonists
EP2029530B1 (en) 2006-06-16 2012-09-19 Syngenta Participations AG Ethenyl carboxamide derivatives useful as microbiocides
WO2008014238A2 (en) 2006-07-24 2008-01-31 Tetralogic Pharmaceuticals Corporation Dimeric iap inhibitors
WO2008014236A1 (en) 2006-07-24 2008-01-31 Tetralogic Pharmaceuticals Corporation Dimeric iap inhibitors
US8329159B2 (en) 2006-08-11 2012-12-11 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US8303944B2 (en) 2006-08-11 2012-11-06 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US20100158862A1 (en) 2006-08-11 2010-06-24 Bristol-Myers Squibb Company Hepatitis C Virus Inhibitors
US7745636B2 (en) 2006-08-11 2010-06-29 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US7659270B2 (en) 2006-08-11 2010-02-09 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US7759495B2 (en) 2006-08-11 2010-07-20 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
WO2008070447A2 (en) 2006-11-21 2008-06-12 Smithkline Beecham Corporation Anti-viral compounds
EP2099778A2 (en) 2006-11-21 2009-09-16 Smithkline Beecham Corporation Amido anti-viral compounds
TWI399380B (zh) 2006-12-20 2013-06-21 Abbott Lab 抗病毒化合物
WO2008074450A2 (en) 2006-12-20 2008-06-26 Nicox S.A. Non-peptidic renin inhibitors nitroderivatives
US8642554B2 (en) 2007-04-12 2014-02-04 Joyant Pharmaceuticals, Inc. Smac mimetic dimers and trimers useful as anti-cancer agents
US7741347B2 (en) 2007-05-17 2010-06-22 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US8173696B2 (en) 2007-06-13 2012-05-08 Baylor University Inhibitors of cysteine proteases and methods of use thereof
US20090004140A1 (en) 2007-06-26 2009-01-01 Yao-Ling Qiu 4-substituted pyrrolidine as anti-infectives
EP2185154A2 (en) 2007-08-03 2010-05-19 Schering Corporation Method of treating cxcr3 mediated diseases using heterocyclic substituted piperazines
US8629171B2 (en) 2007-08-08 2014-01-14 Bristol-Myers Squibb Company Crystalline form of methyl ((1S)-1-((25)-2-(5-(4'-(2-((25)-1((2S)-2-((methoxycarbonyl)amino)-3-methylbutanoyl)-2-pyrrolidinyl)-1H-imidazol-2-yl)-1-pyrrolidinyl)carbonyl)-2-methylpropyl)carbamate dihydrochloride salt
US7728027B2 (en) 2007-08-08 2010-06-01 Bristol-Myers Squibb Company Process for synthesizing compounds useful for treating hepatitis C
GB0801199D0 (en) 2008-01-23 2008-02-27 Acal Energy Ltd Fuel cells
EP2250160B1 (en) 2008-01-25 2015-11-11 Millennium Pharmaceuticals, Inc. Thiophenes and their use as phosphatidylinositol 3-kinase (pi3k) inhibitors
KR20100123717A (ko) 2008-02-12 2010-11-24 브리스톨-마이어스 스큅 컴퍼니 Ｃ형 간염 바이러스 억제제로서의 헤테로시클릭 유도체
JP5314053B2 (ja) 2008-02-12 2013-10-16 ブリストル−マイヤーズ スクイブ カンパニー Ｃ型肝炎ウイルス阻害剤
US7704992B2 (en) 2008-02-13 2010-04-27 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US8147818B2 (en) 2008-02-13 2012-04-03 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
ES2391600T3 (es) 2008-02-13 2012-11-28 Bristol-Myers Squibb Company Imidazoli bifenil imidazoles como inhibidores del virus de la hepatitis C
CN101959506A (zh) 2008-02-28 2011-01-26 雅培制药有限公司 片剂和其制备方法
WO2009136290A1 (en) 2008-05-05 2009-11-12 Aegera Therapeutics, Inc. Functionalized pyrrolidines and use thereof as iap inhibitors
WO2009143361A1 (en) 2008-05-22 2009-11-26 Smithkline Beecham Corporation Amido anti-viral compounds
CA2728933A1 (en) 2008-06-27 2009-12-30 Aegera Therapeutics Inc. Bridged secondary amines and use thereof as iap bir domain binding compounds
PL2540350T3 (pl) 2008-07-22 2014-10-31 Merck Sharp & Dohme Kombinacje makrocyklicznego związku chinoksaliny, który jest inhibitorem proteazy NS3 HCV z innymi środkami przeciw HCV
JP2011529962A (ja) 2008-08-02 2011-12-15 ジェネンテック， インコーポレイテッド Ｉａｐのインヒビター
US7906655B2 (en) 2008-08-07 2011-03-15 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
WO2010015090A1 (en) 2008-08-07 2010-02-11 Aegera Therapeutics Inc. Functionalized pyrrolidines and use thereof as iap inhibitors
UY32099A (es) * 2008-09-11 2010-04-30 Enanta Pharm Inc Inhibidores macrocíclicos de serina proteasas de hepatitis c
US8383094B2 (en) 2008-10-01 2013-02-26 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
WO2010059858A1 (en) 2008-11-19 2010-05-27 Duke University Manassantin compounds and methods of making and using same
JP2010126571A (ja) 2008-11-26 2010-06-10 Toyo Ink Mfg Co Ltd 有機エレクトロルミネッセンス素子材料および有機エレクトロルミネッセンス素子
US8729077B2 (en) 2008-11-28 2014-05-20 Glaxosmithkline Llc Anti-viral compounds, compositions, and methods of use
EP2373172B1 (en) 2008-12-03 2013-07-17 Presidio Pharmaceuticals, Inc. Inhibitors of hcv ns5a
KR20110098779A (ko) 2008-12-03 2011-09-01 프레시디오 파마슈티칼스, 인코포레이티드 Ｈｃｖ ｎｓ5ａ의 억제제
CN102264737A (zh) 2008-12-23 2011-11-30 雅培制药有限公司 抗病毒化合物
CN102245604A (zh) 2008-12-23 2011-11-16 雅培制药有限公司 抗病毒化合物
EP2393359A4 (en) 2009-02-09 2012-10-03 Enanta Pharm Inc COMPOUND DIBENZIMIDAZOLE DERIVATIVES
US8314135B2 (en) 2009-02-09 2012-11-20 Enanta Pharmaceuticals, Inc. Linked dibenzimidazole antivirals
US8637561B2 (en) 2009-02-17 2014-01-28 Enanta Pharmaceuticals, Inc. Linked diimidazole derivatives
US8188132B2 (en) 2009-02-17 2012-05-29 Enanta Pharmaceuticals, Inc. Linked dibenzimidazole derivatives
US8420686B2 (en) 2009-02-17 2013-04-16 Enanta Pharmaceuticals, Inc. Linked diimidazole antivirals
WO2010096462A1 (en) 2009-02-17 2010-08-26 Enanta Pharmaceuticals, Inc Linked diimidazole derivatives
US8242156B2 (en) 2009-02-17 2012-08-14 Enanta Pharmaceuticals, Inc. Linked dibenzimidazole derivatives
US8394968B2 (en) 2009-02-17 2013-03-12 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
TWI438200B (zh) 2009-02-17 2014-05-21 必治妥美雅史谷比公司 Ｃ型肝炎病毒抑制劑
UY32462A (es) 2009-02-23 2010-09-30 Arrow Therapeutics Ltd Derivados de bifenilo novedosos para el tratamiento de infección por virus de hepatitis c 644
CA2753313A1 (en) 2009-02-23 2010-08-26 Presidio Pharmaceuticals, Inc. Inhibitors of hcv ns5a
KR101411889B1 (ko) 2009-02-27 2014-06-27 이난타 파마슈티칼스, 인코포레이티드 Ｃ형 간염 바이러스 억제제
US8426458B2 (en) 2009-02-27 2013-04-23 Enanta Pharmaceuticals, Inc. Hepatitis C Virus inhibitors
US8673954B2 (en) 2009-02-27 2014-03-18 Enanta Pharmaceuticals, Inc. Benzimidazole derivatives
US8101643B2 (en) 2009-02-27 2012-01-24 Enanta Pharmaceuticals, Inc. Benzimidazole derivatives
US8507522B2 (en) 2009-03-06 2013-08-13 Enanta Pharmaceuticals, Inc. Hepatitis C virus inhibitors
CN102427729B (zh) 2009-03-27 2014-09-03 默沙东公司 丙型肝炎病毒复制的抑制剂
BRPI1012282A2 (pt) 2009-03-27 2015-09-22 Presidio Pharmaceuticals Inc inibidores de anel fundidos da hepatite c.
EP2410841A4 (en) 2009-03-27 2012-10-24 Presidio Pharmaceuticals Inc SUBSTITUTED BICYCLIC HCV INHIBITORS
US20110237636A1 (en) 2009-03-30 2011-09-29 Bristol-Myers Squibb Company Hepatitis C Virus Inhibitors
TWI476190B (zh) 2009-03-30 2015-03-11 必治妥美雅史谷比公司 Ｃ型肝炎病毒抑制劑
US8796466B2 (en) 2009-03-30 2014-08-05 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
JP5787876B2 (ja) 2009-04-08 2015-09-30 ビーエーエスエフ ソシエタス・ヨーロピアＢａｓｆ Ｓｅ ピロロピロール誘導体、その製造方法及び半導体としての使用
TW201038559A (en) 2009-04-09 2010-11-01 Bristol Myers Squibb Co Hepatitis C virus inhibitors
US8143414B2 (en) 2009-04-13 2012-03-27 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
EP2419404B1 (en) 2009-04-15 2015-11-04 AbbVie Inc. Anti-viral compounds
JP2012524761A (ja) 2009-04-24 2012-10-18 テイボテク・フアーマシユーチカルズ ジアリールエーテル類
US9139569B2 (en) 2009-05-12 2015-09-22 Merck Sharp & Dohme Corp. Fused tricyclic aryl compounds useful for the treatment of viral diseases
TWI689305B (zh) 2009-05-13 2020-04-01 美商基利法瑪席特有限責任公司 抗病毒化合物
CA2763140A1 (en) 2009-05-29 2010-12-02 Schering Corporation Antiviral compounds composed of three linked aryl moieties to treat diseases such as hepatitis c
US8138215B2 (en) 2009-05-29 2012-03-20 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US8211928B2 (en) 2009-05-29 2012-07-03 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
JP2012528194A (ja) 2009-05-29 2012-11-12 メルク・シャープ・アンド・ドーム・コーポレーション Ｃ型肝炎などの疾患を処置するための３つの整列型アリール部分で構成された抗菌性化合物
US9394279B2 (en) * 2009-06-11 2016-07-19 Abbvie Inc. Anti-viral compounds
NZ591973A (en) 2009-06-11 2013-03-28 Abbott Lab Anti-viral compounds to treat hcv infection
US8937150B2 (en) 2009-06-11 2015-01-20 Abbvie Inc. Anti-viral compounds
US8221737B2 (en) 2009-06-16 2012-07-17 Enanta Pharmaceuticals, Inc. Hepatitis C virus inhibitors
WO2010148006A1 (en) 2009-06-16 2010-12-23 Enanta Pharmaceuticals, Inc. Hepatitis c virus inhibitors
US8609648B2 (en) 2009-07-02 2013-12-17 Enanta Pharmaceuticals, Inc. Hepatitis C virus inhibitors
WO2011004276A1 (en) 2009-07-06 2011-01-13 Pfizer Limited Hepatitis c virus inhibitors
US8354419B2 (en) 2009-07-16 2013-01-15 Vertex Pharmaceuticals Incorporated Benzimidazole analogues for the treatment or prevention of flavivirus infections
EP2462135A1 (en) 2009-08-07 2012-06-13 Janssen R&D Ireland Bis-benzimidazole derivatives as hepatitis c virus inhibitors
US20120172368A1 (en) 2009-09-03 2012-07-05 Koen Vandyck Bis-Benzimidazole Derivatives
EP2473056A4 (en) 2009-09-04 2013-02-13 Glaxosmithkline Llc CHEMICAL COMPOUNDS
US8759332B2 (en) 2009-09-11 2014-06-24 Enanta Pharmaceuticals, Inc. Hepatitis C virus inhibitors
US8815928B2 (en) 2009-09-11 2014-08-26 Enanta Pharmaceuticals, Inc. Hepatitis C virus inhibitors
US8927709B2 (en) 2009-09-11 2015-01-06 Enanta Pharmaceuticals, Inc. Hepatitis C virus inhibitors
US8703938B2 (en) 2009-09-11 2014-04-22 Enanta Pharmaceuticals, Inc. Hepatitis C virus inhibitors
WO2011031934A1 (en) 2009-09-11 2011-03-17 Enanta Pharmaceuticals, Inc. Hepatitis c virus inhibitors
US8822700B2 (en) 2009-09-11 2014-09-02 Enanta Pharmaceuticals, Inc. Hepatitis C virus inhibitors
EP2475256A4 (en) 2009-09-11 2013-06-05 Enanta Pharm Inc HEPATITIS C-VIRUS HEMMER
WO2011050146A1 (en) 2009-10-23 2011-04-28 Glaxosmithkline Llc Chemical compounds
UA108211C2 (uk) 2009-11-04 2015-04-10 Янссен Рід Айрленд Бензімідазолімідазольні похідні
US20110274648A1 (en) 2009-11-11 2011-11-10 Bristol-Myers Squibb Company Hepatitis C Virus Inhibitors
US20110269956A1 (en) 2009-11-11 2011-11-03 Bristol-Myers Squibb Company Hepatitis C Virus Inhibitors
US20110281910A1 (en) 2009-11-12 2011-11-17 Bristol-Myers Squibb Company Hepatitis C Virus Inhibitors
EP2503881B1 (en) 2009-11-25 2015-05-13 Merck Sharp & Dohme Corp. Fused tricyclic compounds and derivatives thereof useful for the treatment of viral diseases
MY179840A (en) 2009-12-04 2020-11-18 National Health Res Inst Proline derivatives
US8653070B2 (en) 2009-12-14 2014-02-18 Enanta Pharmaceuticals, Inc. Hepatitis C virus inhibitors
US8377980B2 (en) 2009-12-16 2013-02-19 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
CA2784748A1 (en) 2009-12-18 2011-06-23 Idenix Pharmaceuticals, Inc. 5,5-fused arylene or heteroarylene hepatitis c virus inhibitors
CN104530079B (zh) 2009-12-18 2017-10-20 北京凯因科技股份有限公司 C型肝炎病毒复制的新型抑制剂
CA2785488A1 (en) 2009-12-22 2011-07-21 Merck Sharp & Dohme Corp. Fused tricyclic compounds and methods of use thereof for the treatment of viral diseases
MX2012007420A (es) 2009-12-24 2012-07-23 Vertex Pharma Analogos para el tratamiento o prevencion de infecciones de flavivirus.
US8362020B2 (en) 2009-12-30 2013-01-29 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
WO2011091446A1 (en) 2010-01-22 2011-07-28 Glaxosmithkline Llc Chemical compounds
BR112012018529A2 (pt) 2010-01-25 2016-08-09 Enanta Pharm Inc inibidores do vírus de hepatite c, sua composição farmacêutica e seu uso, e método para inibição da replicação de um vírus contendo rna
WO2011091532A1 (en) 2010-01-28 2011-08-04 Boehringer Ingelheim International Gmbh Hepatitis c inhibitor compounds
US8178531B2 (en) 2010-02-23 2012-05-15 Enanta Pharmaceuticals, Inc. Antiviral agents
MX2012010252A (es) 2010-03-04 2013-02-01 Enanta Pharm Inc Agentes farmaceuticos en combinacion como inhibidores de la replicacion del virus de hepatitis c (hcv).
AU2011224698A1 (en) 2010-03-09 2012-11-01 Merck Sharp & Dohme Corp. Fused Tricyclic Silyl Compounds and methods of use thereof for the treatment of viral diseases
EP2550267A1 (en) 2010-03-24 2013-01-30 Vertex Pharmaceuticals Incorporated Analogues for the treatment or prevention of flavivirus infections
TW201141857A (en) 2010-03-24 2011-12-01 Vertex Pharma Analogues for the treatment or prevention of flavivirus infections
JP2013522377A (ja) 2010-03-24 2013-06-13 バーテックス ファーマシューティカルズ インコーポレイテッド フラビウイルス感染を処置または予防するためのアナログ
EP2550262A1 (en) 2010-03-24 2013-01-30 Vertex Pharmaceuticals Incorporated Analogues for the treatment or prevention of flavivirus infections
EP2555622A4 (en) 2010-04-09 2013-09-18 Enanta Pharm Inc HEPATITIS C-VIRUS HEMMER
US20110312996A1 (en) 2010-05-17 2011-12-22 Intermune, Inc. Novel inhibitors of hepatitis c virus replication
CA2800530A1 (en) 2010-05-28 2011-12-01 Presidio Pharmaceuticals, Inc. Inhibitors of hcv ns5a
EP2575819A4 (en) 2010-06-04 2013-11-27 Enanta Pharm Inc INHIBITORS OF HEPATITIS C VIRUS
EP2580209A4 (en) 2010-06-09 2013-11-06 Presidio Pharmaceuticals Inc INHIBITORS OF HCV NS5A PROTEIN
NZ605440A (en) 2010-06-10 2014-05-30 Abbvie Bahamas Ltd Solid compositions comprising an hcv inhibitor
US8822520B2 (en) 2010-09-22 2014-09-02 Presidio Pharmaceuticals, Inc. Substituted bicyclic HCV inhibitors
CN103249730A (zh) 2010-09-24 2013-08-14 百时美施贵宝公司 丙型肝炎病毒抑制剂
WO2012041227A1 (en) 2010-09-29 2012-04-05 Merck Sharp & Dohme Corp. Tetracyclic heterocycle compounds for treating hepatitis c viral infection
MX2013003631A (es) 2010-09-29 2013-10-01 Merck Sharp & Dohme Derivados de indol tetraciclicos y sus métodos para el tratamiento de enfermedades virales.
WO2012040923A1 (en) 2010-09-29 2012-04-05 Merck Sharp & Dohme Corp. Tetracyclic indole derivatives and methods of use thereof for the treatment of viral diseases
EP2621279B1 (en) 2010-09-29 2018-04-04 Merck Sharp & Dohme Corp. Fused tetracycle derivatives and methods of use thereof for the treatment of viral diseases
WO2012040924A1 (en) 2010-09-29 2012-04-05 Merck Sharp & Dohme Corp. Fused tetracyclic heterocycle compounds and methods of use thereof for treatment of viral diseases
WO2012050850A1 (en) 2010-09-29 2012-04-19 Merck Sharp & Dohme Corp. Polycyclic heterocycle derivatives and methods of use thereof for the treatment of viral diseases
TWI471670B (zh) 2010-09-29 2015-02-01 Au Optronics Corp 液晶顯示面板
US8921372B2 (en) 2010-11-04 2014-12-30 Theravance Biopharma R&D Ip, Llc Inhibitors of hepatitis C virus
KR20190140486A (ko) 2010-11-17 2019-12-19 길리애드 파마셋 엘엘씨 항바이러스 화합물
RU2452735C1 (ru) 2010-11-30 2012-06-10 Александр Васильевич Иващенко Замещенные азолы, противовирусный активный компонент, фармацевтическая композиция, способ получения и применения
WO2012087976A2 (en) 2010-12-21 2012-06-28 Intermune, Inc. Novel inhibitors of hepatitis c virus replication

Also Published As

Publication number Publication date
SG188951A1 (en) 2013-05-31
NO2017057I2 (no) 2018-11-26
EP3438106A1 (en) 2019-02-06
US9586978B2 (en) 2017-03-07
CY2017031I2 (el) 2018-04-04
KR20140143152A (ko) 2014-12-15
CO6761348A2 (es) 2013-09-30
EP2627651A1 (en) 2013-08-21
US20190015402A1 (en) 2019-01-17
NZ606645A (en) 2014-09-26
KR20140032338A (ko) 2014-03-14
EP2692726A1 (en) 2014-02-05
US10028937B2 (en) 2018-07-24
BR112013005701B1 (pt) 2022-05-10
NO2021039I1 (no) 2021-09-16
JP5834085B2 (ja) 2015-12-16
FR17C1040I1 (pl) 2017-08-12
LUC00038I1 (pl) 2017-10-12
MX344092B (es) 2016-12-05
AU2011316506B2 (en) 2014-06-12
CN104193729A (zh) 2014-12-10
KR101831154B1 (ko) 2018-02-26
FR17C1040I2 (fr) 2018-11-16
CY2017031I1 (el) 2018-04-04
CN106986861A (zh) 2017-07-28
LTPA2017033I1 (lt) 2017-11-10
US8937150B2 (en) 2015-01-20
CA2807847C (en) 2016-09-20
CN103153988B (zh) 2014-07-09
EA024100B1 (ru) 2016-08-31
UY35266A (es) 2015-07-31
UY33667A (es) 2012-04-30
EA033332B1 (ru) 2019-09-30
AR083398A1 (es) 2013-02-21
EA201301158A1 (ru) 2014-07-30
GT201300093A (es) 2014-04-29
US20170157104A1 (en) 2017-06-08
CA2807847A1 (en) 2012-04-19
US20170157105A1 (en) 2017-06-08
MX2013004150A (es) 2013-09-02
PE20140835A1 (es) 2014-08-15
DOP2013000078A (es) 2018-04-30
BR112013005701A2 (pt) 2020-10-13
LUC00038I2 (pl) 2017-12-13
LTC2692346I2 (lt) 2021-11-10
TWI419874B (zh) 2013-12-21
MX2020002151A (es) 2020-07-13
JP2013539791A (ja) 2013-10-28
TW201238948A (en) 2012-10-01
EA201390538A1 (ru) 2014-02-28
KR101586215B1 (ko) 2016-01-18
ECSP13012622A (es) 2013-07-31
NL300901I2 (nl) 2017-11-16
US20150087618A1 (en) 2015-03-26
NO2017057I1 (no) 2017-11-10
EP2692346B1 (en) 2015-12-02
CN103153988A (zh) 2013-06-12
US10039754B2 (en) 2018-08-07
PE20140038A1 (es) 2014-02-20
WO2012051361A1 (en) 2012-04-19
EP2692346A1 (en) 2014-02-05
AU2011316506A1 (en) 2013-02-21
US20120004196A1 (en) 2012-01-05

Similar Documents

Publication Publication Date Title
HUS1700040I1 (hu) Antivirális 1-fenil-2,5-dibenzimidazol-5-il-pirrolidin-származék
CY2017031I2 (el) Αντι-ιικο παραγωγο 1-φαινυλ-2,5-διβενζιμιδαζολ-5-υλ-πυρρολιδινης
HK1250162A1 (zh) 抗病毒化合物
ZA201205788B (en) 1,2,4-triazine-4-amine derivatives
HK1182594A1 (en) N3-substituted-n1-sulfonyl-5-fluoropyrimidinone derivatives n3--n1--5-
ZA201209117B (en) Tetrahydro-pyrido-pyrimidine derivatives
ZA201304282B (en) Pyrazole derivative
EP2585073A4 (en) ANTIVIRAL COMPOUNDS
HK1182109A1 (zh) -三唑酮衍生物
GB2490849B (en) Di-aspirin derivatives
HK1174625A1 (en) Pyrrazolopyridine derivatives
HU1000243D0 (en) 8-hidroxy-quinoline derivatives
HK1188717A1 (zh) 種抗病毒 -苯基- -二苯並咪唑- -基-吡咯烷衍生物
ZA201209248B (en) Amido-tropane derivatives
IL220983A0 (en) 2-aldoximino-5-fluoropyrimidine derivatives